Loss of p53 in esophageal squamous cell carcinoma and the correlation with survival: Analyses of gene mutations, protein expression, and loss of heterozygosity in Japanese patients

Journal of Surgical Oncology

Volumn 104, Issue 2, 2011, Pages 169-175

  Egashira, Akinori ^a   Morita, Masaru ^a   Yoshida, Rintaro ^a   Saeki, Hiroshi ^a   Oki, Eiji ^a   Sadanaga, Noriaki ^a   Kakeji, Yoshihiro ^a   Tsujitani, Shun Ichi ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

esophageal cancer; gene mutation; immunohistochemistry; LOH; p53

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959933173     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21920     Document Type: Article

References (30)

1. Hanahan D, Weinberg RA,: The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
2. Hofseth LJ, Hussain SP, Harris CC,: p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-181. (Pubitemid 38519907)
3. Vogelstein B, Lane D, Levine AJ,: Surfing the p53 network. Nature 2000; 408: 307-310.
4. Vousden KH, Lu X,: Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604. (Pubitemid 37328926)
5. Donehower LA, Harvey M, Slagle BL, et al.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
6. Greenblatt MS, Bennett WP, Hollstein M, et al.: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878. (Pubitemid 24289415)
7. Hainaut P, Hernandez T, Robinson A, et al.: IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998; 26: 205-213. (Pubitemid 28291534)
8. Shi ST, Yang GY, Wang LD, et al.: Role of p53 gene mutations in human esophageal carcinogenesis: Results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999; 20: 591-597. (Pubitemid 29151294)
9. Egashira A, Yamauchi K, Yoshiyama K, et al.: Mutational specificity of mice defective in the MTH1 and/or the MSH2 genes. DNA Repair (Amst) 2002; 1: 881-893.
10. Egashira A, Morita M, Kakeji Y, et al.: p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: Results in Japan and comparisons with other countries. Cancer Sci 2007; 98: 1152-1156. (Pubitemid 46993534)
11. Saeki H, Ohno S, Araki K, et al.: Alcohol consumption and cigarette smoking in relation to high frequency of p53 protein accumulation in oesophageal squamous cell carcinoma in the Japanese. Br J Cancer 2000; 82: 1892-1894. (Pubitemid 30307407)
12. Tanioka Y, Yoshida T, Yagawa T, et al.: Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003; 89: 2116-2121. (Pubitemid 38030912)
13. Kang SY, Han JH, Lee KJ, et al.: Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 2007; 13: 4146-4153.
14. Araki K, Wang B, Miyashita K, et al.: Frequent loss of heterozygosity but rare microsatellite instability in oesophageal cancer in Japanese and Chinese patients. Oncology 2004; 67: 151-158. (Pubitemid 39482684)
15. The Japan Esophageal Society: Japanese classification of esophageal cancer, 10th edition. Tokyo: Kanehara & CO., Ltd; 2008.
16. Coggi G, Bosari S, Roncalli M, et al.: p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-432. (Pubitemid 27051764)
17. Huang J, Hu N, Goldstein AM, et al.: High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis 2000; 21: 2019-2026.
18. Hu N, Huang J, Emmert-Buck MR, et al.: Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. Clin Cancer Res 2001; 7: 883-891. (Pubitemid 32708725)
19. Soussi T, Dehouche K, Beroud C,: p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum Mutat 2000; 15: 105-113. (Pubitemid 30036177)
20. Olivier M, Eeles R, Hollstein M, et al.: The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-614. (Pubitemid 34556481)
21. Mitsudomi T, Hamajima N, Ogawa M, et al.: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 2000; 6: 4055-4063.
22. Pharoah PD, Day NE, Caldas C,: Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 1999; 80: 1968-1973. (Pubitemid 29391282)
23. Uchino S, Saito T, Inomata M, et al.: Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol 1996; 26: 287-292. (Pubitemid 126470685)
24. Kobayashi S, Koide Y, Endo M, et al.: The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 1999; 177: 497-502. (Pubitemid 29331482)
25. Sarbia M, Porschen R, Borchard F, et al.: p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994; 74: 2218-2223.
26. Schneider PM, Stoeltzing O, Roth JA, et al.: P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2000; 6: 3153-3158. (Pubitemid 30637741)
27. Lane DP, Crawford LV,: T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-263. (Pubitemid 9129076)
28. Sarnow P, Ho YS, Williams J, et al.: Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982; 28: 387-394. (Pubitemid 12132769)
29. Harris SL, Levine AJ,: The p53 pathway: Positive and negative feedback loops. Oncogene 2005; 24: 2899-2908. (Pubitemid 40638098)
30. Momand J, Zambetti GP, Olson DC, et al.: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.